Savvy Advisors Inc. Purchases 1,114 Shares of Zoetis Inc. $ZTS

Savvy Advisors Inc. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 54.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,177 shares of the company’s stock after purchasing an additional 1,114 shares during the period. Savvy Advisors Inc.’s holdings in Zoetis were worth $495,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis during the first quarter worth $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis during the first quarter worth $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the first quarter worth $29,000. Cornerstone Planning Group LLC lifted its position in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.1%

Shares of ZTS stock opened at $144.25 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $183.11. The company has a market capitalization of $63.93 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The business’s fifty day moving average is $147.15 and its 200 day moving average is $153.36.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the business posted $1.56 earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZTS. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.